Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Keybanc Maintains Overweight on Baxter Intl, Raises Price Target to $98

Keybanc analyst Matthew Mishan maintains Baxter Intl (NYSE:BAX) with a Overweight and raises the price target from $92 to $98.

byBenzinga Newsdesk

January 4, 2022

1 minute read

Keybanc analyst Matthew Mishan maintains Baxter Intl (NYSE:BAX) with a Overweight and raises the price target from $92 to $98.

Barclays Maintains Equal-Weight on Fisker, Lowers Price Target to $16

By Benzinga Newsdesk

August 9, 9:08 AM

Barclays analyst Brian Johnson maintains Fisker (NYSE:FSR) with a Equal-Weight and lowers the price target from $17 to $16.

FSR

This Biopharma Stock Surges After Offloading Its Ophthalmic Eye Drop Portfolio

By Vandana Singh

May 23, 6:29 AM

Alcon AG (NYSE:ALC) has agreed to acquire Eysuvis (loteprednol etabonate suspension) 0.25% pharmaceutical eye drops from Kala Pharmaceuticals Inc (NASDAQ:KALA). Eysuvis will complement…

ALC

News

Delta Air Lines CFO Says While Approaching 2019 Capacity Provides Scale Benefits, Still Bearing The Cost To Fully Restore Our Network To The Peak Summer Levels

By Benzinga Newsdesk

January 13, 11:23 AM

- Reuters

DAL

AbbVie Reports Positive CHMP Opinion For Risankizumab For Treatment Of Adults With Active Psoriatic Arthritis In EU

By Benzinga Newsdesk

October 15, 8:36 AM

- CHMP positive opinion is based on data from two Phase 3 studies, KEEPsAKE-1 and KEEPsAKE-2[1],[2] - If approved, this will mark the second indication for risankizumab in the EU[3] - Psoriatic arthritis is a systemic

ABBV

Keybanc Maintains Overweight on Baxter Intl, Raises Price Target to $98

Related Posts

Barclays Maintains Equal-Weight on Fisker, Lowers Price Target to $16

This Biopharma Stock Surges After Offloading Its Ophthalmic Eye Drop Portfolio

Delta Air Lines CFO Says While Approaching 2019 Capacity Provides Scale Benefits, Still Bearing The Cost To Fully Restore Our Network To The Peak Summer Levels

AbbVie Reports Positive CHMP Opinion For Risankizumab For Treatment Of Adults With Active Psoriatic Arthritis In EU